Multi-dose vial: difference between revisions
Diff·revision 16 → 17·19:02, 5 Apr 2025
Difference between revision 16 and revision 17 of Multi-dose vial. 3 lines changed; the page grew by 853 bytes.
| Revision 16 — 07:44, 30 Mar 2025 StabilityStig (talk) label community tally as self-reported 10,398 bytes +2,502 | Revision 17 — 19:02, 5 Apr 2025 GlossaryGleb (talk) add confidence interval 11,251 bytes +853 | ||
|---|---|---|---|
| 34 | The 28-day duration of the test and the 28-day default period after puncture are related but not identical claims. The test demonstrates that the preservative system suppresses growth of a substantial deliberate inoculum over 28 days under laboratory conditions; the use period is a practice rule informed by that demonstration. Guidance is explicit that a manufacturer may specify a shorter period, and that a shorter period so specified governs.{{r|usp797,usp51}} | 34 | The 28-day duration of the test and the 28-day default period after puncture are related but not identical claims. The test demonstrates that the preservative system suppresses growth of a substantial deliberate inoculum over 28 days under laboratory conditions; the use period is a practice rule informed by that demonstration. Guidance is explicit that a manufacturer may specify a shorter period, and that a shorter period so specified governs.{{r|usp797,usp51}} |
| 35 | 35 | ||
| + | 36 | Preservative-free preparations intended for parenteral use are single-dose regardless of their volume. This has a direct consequence for reconstituted peptides: a vial reconstituted with [[Sterile water for injection|sterile water for injection]] contains no preservative and is, in compendial terms, a single-dose preparation, whereas one reconstituted with [[Bacteriostatic water|bacteriostatic water for injection]] contains benzyl alcohol and has at least the formulation characteristics of a preserved product — though not the demonstration of effectiveness, which is made for a specific formulation and not for a diluent.{{r|usp797,ppmdv}} | |
| + | 37 | ||
| 36 | == Antimicrobial preservatives == | 38 | == Antimicrobial preservatives == |
| 37 | Preservatives used in injectable products are a small set, constrained by systemic toxicity at the concentrations required, by compatibility with peptides and proteins, and by the pH range over which they remain active. | 39 | Preservatives used in injectable products are a small set, constrained by systemic toxicity at the concentrations required, by compatibility with peptides and proteins, and by the pH range over which they remain active. |
| ⋮ | ⋮ | ||
| 78 | <ref name="fischer2010">Fischer GE, Schaefer MK, Labus BJ, et al. "Hepatitis C virus infections from unsafe injection practices at an endoscopy clinic in Las Vegas, Nevada, 2007–2008." ''Clinical Infectious Diseases'' 51(3):267–273 (2010).</ref> | 80 | <ref name="fischer2010">Fischer GE, Schaefer MK, Labus BJ, et al. "Hepatitis C virus infections from unsafe injection practices at an endoscopy clinic in Las Vegas, Nevada, 2007–2008." ''Clinical Infectious Diseases'' 51(3):267–273 (2010).</ref> |
| 79 | <ref name="brange1993">Brange J, Langkjaer L. "Insulin structure and stability." ''Pharmaceutical Biotechnology'' 5:315–350 (1993).</ref> | 81 | <ref name="brange1993">Brange J, Langkjaer L. "Insulin structure and stability." ''Pharmaceutical Biotechnology'' 5:315–350 (1993).</ref> |
| + | 82 | <ref name="ppmdv">PeptidePedia community reconstitution-practice tally, 2026 (self-reported; no sterility or preservative-effectiveness data; weak evidence — see [[Project:Sourcing_guidelines]]).</ref> | |
| 80 | 83 | ||
| 81 | {{DEFAULTSORT:Multi-dose vial}} | 84 | {{DEFAULTSORT:Multi-dose vial}} |